Evidence map›Paper›PMID 19083101›Full record

ReviewThe AAPS journal2008

Physical approaches for nucleic acid delivery to liver.

Kenya Kamimura, Dexi Liu

Open access · greenAbstract readReview
In one paragraph

Review in The AAPS journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Hemodynamics of a hydrodynamic injection.Molecular therapy. Methods & clinical development · 2014
    Article
  9. Article
  10. Article
  11. Efficient liver gene transfer with foamy virus vectors.Medical science monitor basic research · 2013
    Article
  12. Article
  13. Article
  14. Review
  15. Intracellular delivery and calcium transients generated in sonoporation facilitated by microbubbles.Journal of controlled release : official journal of the Controlled Release Society · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kenya KamimuraDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, 527 Salk Hall, Pittsburgh, PA 15261, USA.
Dexi Liu
University of Pittsburgh · US

Funding

Image-Guided Hydrodynamic Gene DeliveryR01EB007357 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, DEXI · 2008 to 2011
$2.3M
Computer-Assisted Hydrodynamic Gene Delivery for Hemophilia Gene TherapyR01HL098295 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, DEXI · 2010 to 2013
$1.6M
New Polymeric Carriers for Pulmonary Gene DeliveryR01HL075542 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, DEXI · 2004 to 2007
$1.3M
Bifunctional Compounds for Targeted Gene DeliveryR01EB002946 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, DEXI · 2003 to 2006
$1.1M
TARGET SPECIFIC EMULSION FOR SYSTEMIC GENE DELIVERYR29CA072925 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, DEXI · 1997 to 2001
$214k
NCI NIH HHS R29 CA072925NHLBI NIH HHS HL075542NHLBI NIH HHS R01 HL075542NHLBI NIH HHS R01 HL098295NIBIB NIH HHS EB002946NIBIB NIH HHS EB007357NIBIB NIH HHS R01 EB002946NIBIB NIH HHS R01 EB007357
6 · The paper itself

Abstract

The liver is a key organ for numerous metabolic pathways and involves many inherited diseases that, although being different in their pathology, are often caused by lack or overproduction of a critical gene product in the diseased cells. In principle, a straightforward method to fix such problem is to introduce into these cells with a gene-coding sequence to provide the missing gene product or with the nucleic acid sequence to inhibit production of the excessive gene product. Practically, however, success of nucleic acid-based pharmaceutics is dependent on the availability of a method capable of delivering nucleic acid sequence in the form of DNA or RNA to liver cells. In this review, we will summarize the progress toward the development of physical methods for nucleic acid delivery to the liver. Emphasis is placed on the mechanism of action, pros, and cons of each method developed so far. We hope the information provided will encourage new endeavor to improve the current methodologies or develop new strategies that will lead to safe and effective delivery of nucleic acids to the liver.

Indexed as

DNAElectroporationGene DeletionGenetic TherapyGene Transfer TechniquesHumansInjectionsLiverLiver DiseasesPharmaceutical PreparationsRNASafetySequence DeletionDNAPharmaceutical PreparationsRNA

Identifiers

PMID19083101
PMCPMC2628207
OpenAlexW2071902136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.